Neuroleptic Malignant Syndrome in a Patient with Tongue Cancer: A Report of a Rare Case
Open Access
- 18 June 2013
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Dentistry
- Vol. 2013, 1-5
- https://doi.org/10.1155/2013/542130
Abstract
Background. Neuroleptic malignant syndrome (NMS) is a rare but life-threatening complication of neuroleptic drugs, which are used widely in head and neck cancer (HANC) patients who develop delirium.Methods and Results. Postoperative delirium in a 39-year-old man with tongue cancer was treated with haloperidol and chlorpromazine. Three days after the first administration of antipsychotics, the patient exhibited elevated body temperature, autonomic and extrapyramidal symptoms, and impaired consciousness. A definitive diagnosis was made using the research diagnostic criteria for NMS in the DSM-IV, and the antipsychotics were immediately discontinued. The patient was given dantrolene and bromocriptine to treat the NMS. The patient’s hyperthermia, elevated creatinin kinase (CK), and muscle rigidity improved gradually, with all symptoms of NMS resolving completely by 13 days after the diagnosis.Conclusions. HANC surgeons must be alert for early signs of NMS and use antipsychotics conservatively to avoid NMS and its potentially fatal outcome.Keywords
This publication has 27 references indexed in Scilit:
- An International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria Using the Delphi MethodBritish Journal of Psychology, 2011
- Risk factors for postoperative delirium in patients undergoing head and neck cancer surgeryInternational Journal of Oral & Maxillofacial Surgery, 2005
- Severe and Uncommon Involuntary Movement Disorders due to Psychotropic DrugsPharmacopsychiatry, 2004
- Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndromeAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2002
- Neuroleptic Malignant Syndrome and OlanzapineJournal of Clinical Psychopharmacology, 2000
- Neuroleptic malignant syndrome during haloperidol treatment in a cancer patientSupportive Care in Cancer, 1998
- Is the Predisposition to Neuroleptic Malignant Syndrome Genetically Transmitted?The British Journal of Psychiatry, 1991
- Neuroleptic malignant syndrome. Review of response to therapyArchives of Internal Medicine, 1989
- The neuroleptic malignant syndrome: agent and host interactionActa Psychiatrica Scandinavica, 1986
- Neuroleptic Malignant SyndromeNew England Journal of Medicine, 1985